Global Information Lookup Global Information

Betrixaban information


Betrixaban
Clinical data
Trade namesBevyxxa
Other namesPRT054021, PRT064445
AHFS/Drugs.combevyxxa
Routes of
administration		By mouth
ATC code
  • B01AF04 (WHO)
Legal status
Legal status
  • US: ℞-only
Pharmacokinetic data
Protein binding60%
Elimination half-life19–27 hrs
Duration of action≥72 hrs
Excretion85% feces, 11% urine
Identifiers
IUPAC name
  • N-(5-Chloropyridin-2-yl)-2-([4-(N,N-dimethylcarbamimidoyl)benzoyl]amino)-5-methoxybenzamide
CAS Number
  • 330942-05-7 ☒N
PubChem CID
  • 10275777
DrugBank
  • DB12364 checkY
ChemSpider
  • 18981107 checkY
UNII
  • 74RWP7W0J9
KEGG
  • D08873
ChEBI
  • CHEBI:140421
ChEMBL
  • ChEMBL512351 checkY
CompTox Dashboard (EPA)
  • DTXSID10954727 Edit this at Wikidata
ECHA InfoCard100.207.746 Edit this at Wikidata
Chemical and physical data
FormulaC23H22ClN5O3
Molar mass451.91 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
InChI
  • InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31) checkY
  • Key:XHOLNRLADUSQLD-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Betrixaban (trade name Bevyxxa) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor.[1] Betrixaban is FDA approved for venous thrombosis prevention in adults hospitalized for an acute illness who are at risk for thromboembolic complications.[2] Compared to other directly acting oral anticoagulants betrixaban has relatively low renal excretion and is not metabolized by CYP3A4.[3]

  1. ^ Eriksson BI, Quinlan DJ, Weitz JI (2009). "Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development". Clinical Pharmacokinetics. 48 (1): 1–22. doi:10.2165/0003088-200948010-00001. PMID 19071881. S2CID 35948814.
  2. ^ "Approved Drugs - FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients". Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration. Retrieved 2018-10-29.
  3. ^ Huisman MV, Klok FA (May 2018). "Pharmacological properties of betrixaban". European Heart Journal Supplements. 20 (Suppl E): E12–E15. doi:10.1093/eurheartj/suy016. PMC 6016700. PMID 29977164.

and 7 Related for: Betrixaban information

Request time (Page generated in 0.5247 seconds.)

Betrixaban

Last Update:

Betrixaban (trade name Bevyxxa) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. Betrixaban is FDA approved for venous thrombosis...

Word Count : 704

Anticoagulant

Last Update:

inhibitor (dabigatran) and factor Xa inhibitor (rivaroxaban, apixaban, betrixaban and edoxaban), and they have been shown to be as good or possibly better...

Word Count : 8726

Portola Pharmaceuticals

Last Update:

the authorisation (approved) Andexanet for the 28 countries of the EU. Betrixaban (Bevyxxa), an oral direct FXa inhibitor for prevention of thrombosis;...

Word Count : 634

Direct factor Xa inhibitors

Last Update:

(Eliquis) from Bristol-Myers Squibb, edoxaban (Lixiana) from Daiichi, and betrixaban (Bevyxxa) from Portola Pharmaceuticals. Xabans that never reached the...

Word Count : 1525

ATC code B01

Last Update:

etexilate B01AF01 Rivaroxaban B01AF02 Apixaban B01AF03 Edoxaban B01AF04 Betrixaban B01AF51 Rivaroxaban and acetylsalicylic acid B01AX01 Defibrotide B01AX04...

Word Count : 346

Factor X

Last Update:

Xa has been developed. These include the drugs rivaroxaban, apixaban, betrixaban, LY517717, darexaban (YM150), edoxaban and 813893. These agents have several...

Word Count : 3337

Discovery and development of direct Xa inhibitors

Last Update:

Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. Betrixaban (Bevyxxa) was approved in the US in 2017. Heparin was discovered by Jay...

Word Count : 4917
PDF Search Engine © AllGlobal.net